This inventor holds 3 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Iovance Biotherapeutics, Inc.. Active years: 2019-2026.
Company Filing History:
Years Active: 2019-2026
Title: Inventor Spotlight: Anand Veerapathran
Introduction: Anand Veerapathran, a notable inventor based in Tampa, FL, has made significant contributions to the field of biomedicine, particularly in cancer immunotherapy. With two patents to his name, Anand is at the forefront of innovative solutions designed to enhance cancer treatment.
Latest Patents: Anand's latest patent, titled "Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion," focuses on compositions and methods involving isolated artificial antigen-presenting cells (aAPCs). These aAPCs comprise myeloid cells, which are genetically modified using viral vectors, such as MOLM-14 and EM-3 myeloid cells. The innovative approach includes the endogenous expression of HLA-AB/C, ICOS-L, and CD58. The viral vectors used carry nucleic acids encoding CD86 and potentially 4-1BBL and/or OX40L, enabling the myeloid cells to effectively express these critical proteins. Additionally, the patent outlines methods for expanding tumor-infiltrating lymphocytes (TILs) utilizing aAPCs and discusses potential treatment methodologies for cancers using TILs after expansion.
Career Highlights: Anand Veerapathran plays an integral role at Iovance Biotherapeutics, Inc., a company dedicated to advancing cell therapy for cancer treatment. His work emphasizes the importance of engineered cellular therapies in enhancing the effectiveness of cancer treatments, making him an essential figure in the fight against cancer.
Collaborations: Throughout his career, Anand has collaborated with talented individuals, including coworkers Aishwarya Gokuldass and Brian Rabinovich. These partnerships are key in driving forward innovative solutions and ensuring the practical application of groundbreaking research in the field of cancer therapy.
Conclusion: With a focus on advancing cancer treatment through innovative research and technological advancements, Anand Veerapathran exemplifies the spirit of modern inventorship. His work in developing artificial antigen-presenting cells is a testament to the potential of scientific innovation in transforming the landscape of cancer treatment. As he continues to explore new avenues in immunotherapy, Anand's contributions stand to inspire future developments in the field.